CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Autres langues Charles River Laboratories International, Inc.

Actions

CRL

US1598641074

Recherche biotechnologique et médicale

Marché Fermé - NYSE Autres places de cotation 22:00:02 25/06/2026			Pré-ouverture 13:48:30
212,71 ^USD	+5,25 %		212,21	-0,24 %

18/06	Charles River Laboratories et Eli Lilly s'associent pour optimiser une plateforme d'IA via l'expertise en tests non cliniques	CI
18/06	CHARLES RIVER LABORATORIES INTERNATIONAL, INC. : Rothschild & Co Redburn persiste à l'achat	ZM

Autres langues

18/06	Charles River Laboratories International, Inc. and Eli Lilly and Company Enter Collaboration to Optimize Ai/Ml Platform Through Nonclinical Testing Expertise
18/06	Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise
17/06	Charles River Laboratories Shares Rise After Morgan Stanley Upgrade
05/06	Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says
01/06	Charles River Laboratories to Present at William Blair and Jefferies Conferences
13/05	Charles River Laboratories, Medipost Sign MoU on GMP-Compliant Testing
13/05	Charles River Laboratories and Medipost sign non-exclusive MoU to advance GMP testing solutions
13/05	Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
13/05	Charles River Laboratories and MEDIPOST Co., Ltd. Sign Non-Exclusive MOU to Collaborate on GMP-Compliant Testing and Commercial and Marketing Efforts
11/05	Charles River Laboratories International, Inc. Approves Ratification of PricewaterhouseCoopers LLP as Independent Auditors
11/05	Charles River Laboratories International, Inc. Announces Board Elections
11/05	Charles River Laboratories International, Inc. Accelerates Digital Pathology with Ai-Powered End-To-End Workflow
11/05	Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow
08/05	Charles River Laboratories International, Inc. Seeks M&A Opportunities
08/05	Charles River Laboratories International : Quarterly Report for Quarter Ending March 28, 2026 (Form 10-Q)
07/05	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.
07/05	Charles River Laboratories International, Inc. Reports Earnings Results for the First Quarter Ended March 28, 2026
07/05	Charles River Laboratories Q1 Adjusted Earnings Decline, Revenue Rises; Maintains 2026 Earnings Guidance
07/05	(CRL) Charles River Laboratories International Expects 2026 Non-GAAP EPS Range $10.80 - $11.30, vs. FactSet Est of $11.08
07/05	Earnings Flash (CRL) Charles River Laboratories International, Inc. Posts Q1 Adjusted EPS $2.06 per Share, vs. FactSet Est of $1.94
07/05	Charles River beats quarterly estimates on steady demand for drug development services
07/05	Earnings Flash (CRL) Charles River Laboratories International, Inc. Reports Q1 Revenue $995.8M, vs. FactSet Est of $977.5M
07/05	Earnings Flash (CRL) Charles River Laboratories International, Inc. Reports Q1 Revenue $995.8M, vs. FactSet Est of $977.5M
07/05	Charles River Laboratories International : Q1 2026 Earnings Presentation
07/05	Charles River: Q1 Earnings Snapshot